These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 20666742)
1. Influence of biofilm formation in the susceptibility of Pseudomonas aeruginosa from Brazilian patients with cystic fibrosis. Ferreira AG; Leão RS; Carvalho-Assef AP; Folescu TW; Barth AL; Marques EA APMIS; 2010 Aug; 118(8):606-12. PubMed ID: 20666742 [TBL] [Abstract][Full Text] [Related]
2. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response. Ciofu O APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154 [TBL] [Abstract][Full Text] [Related]
3. [Investigation of biofilm formation and relationship with genotype and antibiotic susceptibility of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis]. Coban AY; Ciftci A; Onuk EE; Erturan Z; Tanriverdi Cayci Y; Durupinar B Mikrobiyol Bul; 2009 Oct; 43(4):563-73. PubMed ID: 20084909 [TBL] [Abstract][Full Text] [Related]
4. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. Hill D; Rose B; Pajkos A; Robinson M; Bye P; Bell S; Elkins M; Thompson B; Macleod C; Aaron SD; Harbour C J Clin Microbiol; 2005 Oct; 43(10):5085-90. PubMed ID: 16207967 [TBL] [Abstract][Full Text] [Related]
5. Anaerobic culture conditions favor biofilm-like phenotypes in Pseudomonas aeruginosa isolates from patients with cystic fibrosis. O'May CY; Reid DW; Kirov SM FEMS Immunol Med Microbiol; 2006 Dec; 48(3):373-80. PubMed ID: 17052266 [TBL] [Abstract][Full Text] [Related]
6. Mucoid Pseudomonas aeruginosa isolates maintain the biofilm formation capacity and the gene expression profiles during the chronic lung infection of CF patients. Lee B; Schjerling CK; Kirkby N; Hoffmann N; Borup R; Molin S; Høiby N; Ciofu O APMIS; 2011 Apr; 119(4-5):263-74. PubMed ID: 21492226 [TBL] [Abstract][Full Text] [Related]
7. In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients. Fernández-Olmos A; García-Castillo M; Maiz L; Lamas A; Baquero F; Cantón R Int J Antimicrob Agents; 2012 Aug; 40(2):173-6. PubMed ID: 22727530 [TBL] [Abstract][Full Text] [Related]
8. How much do Pseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis? VanDevanter DR; Van Dalfsen JM Pediatr Pulmonol; 2005 Jun; 39(6):504-6. PubMed ID: 15830388 [TBL] [Abstract][Full Text] [Related]
9. Stationary biofilm growth normalizes mutation frequencies and mutant prevention concentrations in Pseudomonas aeruginosa from cystic fibrosis patients. García-Castillo M; del Campo R; Baquero F; Morosini MI; Turrientes MC; Zamora J; Cantón R Clin Microbiol Infect; 2011 May; 17(5):704-11. PubMed ID: 20673272 [TBL] [Abstract][Full Text] [Related]
10. Comparison of antibiotic susceptibility and plasmid content, between biofilm producing and non-producing clinical isolates of Pseudomonas aeruginosa. Delissalde F; Amábile-Cuevas CF Int J Antimicrob Agents; 2004 Oct; 24(4):405-8. PubMed ID: 15380270 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa. Tré-Hardy M; Traore H; El Manssouri N; Vanderbist F; Vaneechoutte M; Devleeschouwer MJ Int J Antimicrob Agents; 2009 Oct; 34(4):370-4. PubMed ID: 19505804 [TBL] [Abstract][Full Text] [Related]
12. Characterization of clonal strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients in Ontario, Canada. Beaudoin T; Aaron SD; Giesbrecht-Lewis T; Vandemheen K; Mah TF Can J Microbiol; 2010 Jul; 56(7):548-57. PubMed ID: 20651854 [TBL] [Abstract][Full Text] [Related]
13. Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model. Tré-Hardy M; Macé C; El Manssouri N; Vanderbist F; Traore H; Devleeschouwer MJ Int J Antimicrob Agents; 2009 Jan; 33(1):40-5. PubMed ID: 18801647 [TBL] [Abstract][Full Text] [Related]
14. Otopathogenic Pseudomonas aeruginosa strains as competent biofilm formers. Wang EW; Jung JY; Pashia ME; Nason R; Scholnick S; Chole RA Arch Otolaryngol Head Neck Surg; 2005 Nov; 131(11):983-9. PubMed ID: 16301370 [TBL] [Abstract][Full Text] [Related]
15. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients. Meluleni GJ; Grout M; Evans DJ; Pier GB J Immunol; 1995 Aug; 155(4):2029-38. PubMed ID: 7636254 [TBL] [Abstract][Full Text] [Related]
16. Effects of ginseng on Pseudomonas aeruginosa motility and biofilm formation. Wu H; Lee B; Yang L; Wang H; Givskov M; Molin S; Høiby N; Song Z FEMS Immunol Med Microbiol; 2011 Jun; 62(1):49-56. PubMed ID: 21303421 [TBL] [Abstract][Full Text] [Related]
17. Pseudomonas aeruginosa diversity in distinct paediatric patient groups. Tramper-Stranders GA; van der Ent CK; Wolfs TF; Kimpen JL; Fleer A; Johansen U; Johansen HK; Høiby N Clin Microbiol Infect; 2008 Oct; 14(10):935-41. PubMed ID: 18752596 [TBL] [Abstract][Full Text] [Related]
18. Differences in biofilm development and antibiotic susceptibility among Streptococcus pneumoniae isolates from cystic fibrosis samples and blood cultures. García-Castillo M; Morosini MI; Valverde A; Almaraz F; Baquero F; Cantón R; del Campo R J Antimicrob Chemother; 2007 Feb; 59(2):301-4. PubMed ID: 17142818 [TBL] [Abstract][Full Text] [Related]